Johnson Financial Group Inc. Has $2.95 Million Holdings in Pfizer Inc. $PFE

Johnson Financial Group Inc. grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 40.5% in the 2nd quarter, Holdings Channel reports. The fund owned 121,497 shares of the biopharmaceutical company’s stock after buying an additional 35,003 shares during the period. Johnson Financial Group Inc.’s holdings in Pfizer were worth $2,945,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in PFE. GKV Capital Management Co. Inc. acquired a new position in Pfizer during the 1st quarter worth approximately $27,000. Curio Wealth LLC grew its stake in shares of Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,098 shares during the last quarter. Bayforest Capital Ltd acquired a new position in shares of Pfizer during the first quarter worth $28,000. Harbor Asset Planning Inc. bought a new position in shares of Pfizer in the 2nd quarter valued at $29,000. Finally, Evelyn Partners Asset Management Ltd acquired a new stake in shares of Pfizer during the 2nd quarter valued at $33,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

PFE stock opened at $25.72 on Thursday. The firm has a market cap of $146.21 billion, a PE ratio of 13.68, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The stock has a 50-day moving average price of $24.94 and a 200-day moving average price of $24.55. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.69.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. The business had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. The ex-dividend date is Friday, November 7th. Pfizer’s payout ratio is presently 100.00%.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on PFE shares. Guggenheim upped their price objective on Pfizer from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Monday. Scotiabank assumed coverage on shares of Pfizer in a report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price target on the stock. Citigroup boosted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. UBS Group restated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. Finally, Morgan Stanley reduced their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a report on Friday, October 10th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $28.39.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.